Figure 4
From: Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma
BET and PI3K inhibition are synergistic in BL. (A) Boxplots of CI show drug interactions of PI3K inhibitors (idelalisib), the AKT inhibitor MK-2206 and mTOR inhibitor (everolimus). CI could not be calculated for all cell lines (cell lines with values <2 are shown). (B) Relative viability (%) data in a 10 × 10 matrix experiment (mean of duplicate values) for combinations of OTX015 with idelalisib, MK-2206 and everolimus. Drugs and respective concentrations are listed on x and y axes. The effect on viability is colour coded (green viability 100%, red 1%). The diagonal box marks viability data used for constant-concentration-ratio analysis of drug interaction, which resulted in the Fa-CI plots (Fraction affected combination index35). Fa-CI plot shows CI on y-axis as a function of effect level of the drug combination (Fa; fraction of dead cells compared to control) on x-axis. Data points below the horizontal line (CI = 1) indicate synergy.
